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jJ-Amyloid of Alzheimer's Disease Induces Reactive Gliosis 
That Inhibits Axonal Outgrowth 
DAVIDR. CANNING,* ROBERTJ. MCKEON,* DAVIDA. DEWITT,* GEORGEPERRY,t 
JEROME R. WUJEK,:!: R. C. A. FREDERICKSON,:j: AND JERRY SILVER* 
Departments of *Neurosciences and t Pathology, Case Western Reserve University, School of Medicine, 10900 Euclid Avenue, 
Cleveland, Ohio 44106-4975; and :j:Gliatech, Inc., 23420 Commerce Park Road, Cleveland, Ohio 44122 
Pathological lesions in the brains of patients with 
Alzheimer's disease (AD) are characterized by dense de-
posits of the protein ,B-amyloid. The link between the 
deposition of ,B-amyloid in senile plaques and AD-asso-
ciated pathology is, at present, controversial since 
there have been conflicting reports on whether the 39-
43 amino acid ,B-amyloid sequence is toxic or trophic to 
neurons. In this report, we show that ,8-amyloid peptide 
when presented as an insoluble substrate which mimics 
its conformation in vivo can induce cortical glial cells in 
vitro and in vivo to locally deposit chondroitin sulfate 
containingproteoglycan. In vitro the proteoglycan-con-
taining matrix deposited by glia on ,8-amyloid blocks the 
usual ability of the peptide to allow cortical neurons to 
adhere and grow. Chondroitin sulfate-containing pro-
teoglycan was also found in senile plaques of human AD 
tissue. We suggest that an additional effect of ,8-amyloid 
in the brain, which compounds the direct effects of ,8-
amyloid on neurons, is mediated by the stimulation of 
astroglia to become reactive. Once in the reactive state, 
glial cells deposit large amounts of growth-inhibitory 
molecules within the neuropil which could impair neuro-
nal process survival and regeneration leading to neu-
rite retraction and/or dystrophy around senile plaques 
in AD. © 1993 Academic Press, Inc. 
INTRODUCTION 
Astrogliosis is a classic hallmark of trauma and dis-
ease of the central nervous system (5, 6). It is believed 
that the role of gliosis in the adult is to wall off the area 
of injury which, in turn, prevents local regeneration of 
neuronal processes (25). Recently, a molecular compo-
nent associated with the extracellular matrix of astro-
glial scars following trauma has been shown to be a 
c~ondroitin-6-sulfate-containing proteoglycan (21). In 
lnVD; this proteoglycan, found in the adult cortex, colo-
~alizes with intensely GFAP-positive astrocytes in and 
llll:rnediately adjacent to induced scars, but not with 
other GF AP-positive astrocytes distant from the injury 
site (21). Neurons fail to elaborate axons in vitro on the 
surface of scars removed intact from adults, unless the 
glycosaminoglycan chains are digested with chondroi-
tinase, suggesting that chondroitin sulfate-containing 
proteoglycan deposition may be involved in limiting the 
growth of regenerating axons in the CNS (22). This idea 
is supported by the finding that certain proteoglycans 
found during development have been shown to be regu-
latory to axonal outgrowth. For instance a chondroitin 
sulfate/keratan sulfate-containing proteoglycan, lo-
cated on astrocytes in boundary regions of the develop-
ing embryo, limits axon elongation in vitro (7, 32) and a 
chondroitinase-sensitive proteoglycan regulates the 
patterning ofaxons in the retina (4). 
Apart from trauma, gliosis may be a normal conse-
quence of senescence in the brain and especially in 
neurodegenerative diseases, where there is an increase 
in reactive glia in response to failing CNS mechanisms 
(9,12, 18, 26). Accordingly, astrogliosis could playa fun-
damental role in the development of pathological le-
sions in Alzheimer's disease (AD) (10). In the AD brain, 
reactive astrocytes are found in high abundance around 
molecularly heterogenous cores of IJ-amyloid found 
within senile plaques (9, 12, 13,23). Also, the presence 
of various sulfated proteoglycans in association with 
amyloid fibrils (29, 30, 31, 37) suggests that reactive 
gliosis could contribute specified extracellular matrix 
components to the forming IJ-amyloid aggregate. In-
deed, the plaque-related glial interactions may be trig-
gered by the deposition of IJ-amyloid (19) and might rep-
resent an attempt to wall off the IJ-amyloid core. 
Neither the source of plaque-associated proteogly-
cans nor the effect these molecules have on neuronal 
survival or neurite dystrophy in AD are known. In this 
report, we have investigated the hypothesis that neurite 
retraction or neuronal death in the AD brain is a conse-
quence of secondary cellular reactions in the form of a 
functionally reactive gliosis, triggered by insoluble 1-40 
and 25-35 peptide fragments of IJ-amyloid variously re-
ported to be neurotoxic (see the complete issue of N euro-
biol. Aging 13(5) for up-to-date review). This reactive 
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gliosis, we propose, leads to the deposition of inhibitory 
molecules which are severely adverse to neuronal pro-
cess survival. 
METHODS 
In Vitro Spot Assay 
For preparation of substrates for the spot assays, 0.5-
1 ,ul of a 2 roM solution of (J-amyloid peptides (1-40 and 
25-35 amino acids were obtained from Bachem Califor-
nia Inc., scrambled 25-35 and scrambled 1-40 kindly 
donated by Gliatech, Inc.) were allowed to air-dry under 
sterile conditions onto nitrocellulose-coated 35-mm pe-
tri dishes or Flaskette chambers (for time-lapse video-
microscopy). This produced peptide spots in the range 
of 0.7-1.2 mm in diameter which visibly adhered to the 
surface of the dish and persisted for the duration of the 
experiments (confirmed by ponceau S staining of pep-
tide). Prior to seeding cells, substrates were overlayed 
with a 5 ,ug/ml solution of laminin in calcium-magne-
sium-free Hanks' balanced salt solution (CMF). 
Culture of Cortical Neurons 
Cortical neurons were obtained from Embryonic Day 
16 rat embryos. Following removal of fetuses from the 
mother, cerebral cortices were removed into CMF and 
cut into small pieces and trypsinized for 10 min at 37°C. 
Following the addition of DMEM-F12 supplemented 
with 10% FCS, cells were resuspended to a determined 
cell density and plated onto prepared peptide spot sub-
strates. For seeding onto conditioned spots, glial cells 
were first removed from the dishes after 2-14 days by 
extensive washes with sterile distilled water, after which 
cortical neurons were seeded as above. 
Filter Implant Assay 
For testing the in vivo response to (J-amyloid peptides, 
pieces of Millipore filter either impregnated with (J-
amyloid peptide (n = 10) or saline (control; n = 10) were 
implanted into the cerebral cortex of neonatal rats. 
Briefly, both groups of PO animals were anesthetized on 
ice. An incision was made on the dorsal surface of the 
head and the skin was retracted. The skull was cleaned 
of the periosteum and a small rectangular opening made 
through the skull. Next, a 2 X 2-mm piece of sterile 
nitrocellulose filter (Millipore Corp.) was implanted 
into the cerebral cortex, and the incision was closed. 
After 30 days animals were anesthetized with chloral 
hydrate and perfused with 4 % paraformaldehyde. The 
brains were postfixed for 4 h in the same fixative and 
then cryoprotected with sucrose prior to cryostat sec-
tioning and staining for the presence of chondroitin sul-
fate-containing proteoglycan. Sections from the brains 
of these animals were also stained for the presence of 
(J-amyloid (antibody kindly provided by 'G. Perry) 
showed that (J-amyloid does not noticeably dissi and 
over the 30-day time period, remaining in the Milll Pate 
filters. POre 
Culture of Glial Cells 
Glial cel.ls were obtained.from PO-P2 neonatal rats b 
the followmg method. Brams were dissected into Cl\1~ 
and then left and right cerebral cortices were freed 
di t · d' ~ surroun ng Issue an cut mto small (0.5 mm) pie 
D· " . . 1 ces t ISSO.cI~~lOn(Omto :)mg e ?ells was achieved by briefi; 
rypsmIzmg .25"/0 the tIssue and passing it through: 
Nitex filter (60 ,um). The cell suspension was th a· 
seeded into Falcon tissue culture flasks in DMEl\1-F~~ 
supplemented with 10% FCS. After 3 days, nonadherent 
cells were lightly shaken off and the medium was 
changed. Before the cells became confluent, adherent 
cells were passaged into fresh flasks by trypsinizatio 
(0.25%) for 15 min at 37°C and replated in DMEM-FI~ 
supplemented with 10% FCS. Under these conditions 
approximately 95% of the cells were found to be GFAP 
positive. At this point some cultures were incubated 
with a small volume (1 ,ulIO ml-1) of 0.06-,um Fluores-
bri~e carboxy~ate microspheres (Polysciences Inc.) 
WhICh are readily phagocytosed by glial cells and allows 
identification of cells on phase opaque substrates with 
fluorescent optics. Cells were passaged an additional 
two times before use in the substrate assays. For seeding 
onto peptides in the spot assays, glial cells were re-
moved from these cultures following a similar trypsin-
ization protocol, resupended to a determined concen-
tration, and plated onto prepared peptide substrates (as 
described above). 
Timelapse Video microscopy 
Once seeded with glia or neurons, time-lapse video-
microscopy was performed on selected cultures using an 
inverted Zeiss microscope at various magnifications. 
Time-lapsed cultures were maintained at 37°C for up to 
3 days with a thermostatically controlled heated air 
blower and filmed using a Hamamatsu CCD camera. 
Films were made of cells on and off the (J-amyloid spots ( 
after differing times postseeding (from Time 0 to 14 
days postseeding). Under either Nomarski or phase- I 
contrast optics, images were taken every 100-360 s us- \ 
ing a MetelTek shutter control system operated by an j 
Image 1 system. Digitized images were averaged, con- \ 
trast-enhanced where required, and stored on a Pan- ) 
sonic LF 7010 optical disc recorder. Selected videoprints ) 
were made from stored images with a Sony 500-W video 
printer. ) 
Immunohistochemistry 
For immunocytochemistry, cultures were briefly 
rinsed in PBS and fixed for 12 h at 4°C with 4% formal 
• '-~ ~ - ~~-.- ,~q '" ,i ~J;-." ... """""" .. ~ ... ' ~, ... r_l'.r.': ''\:'~'''''~J1~<".!L'1.I-~";j~-r.>tf~~Cl:':,;.rW>i~'it~~~j~~;(i~·:&i~£jl;(!''Mi~jiY:~ 
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saline. For the filter implants, brains were perfused with 
{ the same fix and cryosectioned after which sections 
were treated the same as cultures. Fixed cultures and 
i sections were washed extensively with PBS and blocked 
for 2 h with 0.1 % BSA/4% NGS in PBS. Cultures and 
i sections were then exposed to a mixture of antibodies: 
GF AP (Accurate Chemical, specific for glial acidic fi-
{ brillar protein) and CS-56, (ICN ImmunoBiologicals, 
which recognizes chondroitin 6-sulfate-containing pro-
( teoglycans), optimally diluted in staining buffer (0.01 % 
BSA/O.4% NGS in PBS containing 0.01% Tween 20). 
After 1 h, the primary cocktail was washed away with 
multiple changes of staining buffer and then exposed to 
an optimally diluted mixture of biotinylated goat anti-
mouse IgM and fluorescein-conjugated goat anti-rabbit 
IgG in staining buffer. After incubation with secondary 
cocktail, cultures were washed as before and incubated 
with strepavidin-conjugated Texas Red (Amersham). 
Cultures were rinsed and coverslipped in Citifluor (Citi-
fluor Ltd.) and viewed on a Leitz Orthoplan 2 micro-
scope fitted for phase-contrast, DIC, and fluorescence 
optics. Control staining was carried out as follows. Cul-
tures which had either or both primaries omitted in the 
above protocol did not show any significant staining. 
Likewise, peptide spots exposed to culture medium 
alone for 14 days in the absence of cells stained negative 
with CS-56. The presence of chondroitin sulfate proteo-
glycan in our cultures and filter implants was confirmed 
with another monoclonal antibody, 3B3, which recog-
nizes the sugar stubs of chondroitin-6-sulfate glycosami-
noglycan side chains near the protein core of the proteo-
glycan after chondroitinase digestion. 
For immunocytochemistry of AD tissue, human hip-
pocampus and frontal cortex were obtained postmor-
tem, fixed in Methacarn (MeOH, 60%; acetic acid, 10%; 
chloroform, 30%), and embedded in paraffin wax. 
1 Chondroitinase ABC, heparinase, or heparitinase were 
applied to the sections overnight at 20°C in Tris-buf-
l! fered saline (pH 7.6). Sections were processed for immunostaining using the peroxidase-antiperoxidase 
1 
method, with 3,3,5,5-diaminobenzidine tetrahydrochlo-
ride as the substrate. The presence of GFAP-positive 
) 
astrocytes was visualized using polyclonal anti-GFAP 
with alkaline phosphatase-linked anti-rabbit IgG and 
Fast Blue R (biotin-avidin). The 3B3 monoclonal anti-
1 body recognizes the sugar stubs of chondroitin-6-sulfate 
1 
glycosaminoglycan side chains near the protein core of 
the proteoglycan after chondroitinase digestion. 
1 
j 
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RESULTS 
A.dherence of Cortical Neurons to (3-Amyloid 
~ To examine the interaction between substrate bound 
-amyloid and neurons, we first challenged neurons in 
Culture with immobilized synthetic peptides of the 39-
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PEPTIDE SPOT 
THE VALUES REPRESENT THE 
RATIO OF NEURONS PER UNIT 
AREA ON THE PEPTIDE SPOTS AS 
COMPARED TO AN EOUIVALENT 
AREA AWAY FROM THE SPOT 
AFTER 48HRS IN CULTURE. 
SCR25·53 CONDITIONED 25-35 
FIG.!. Density of cortical neurons on ~-amyloid peptide spots in 
vitro. The values represent the ratio of neurons per unit area on the 
peptide spots as compared to an equivalent area away from the spot 
after 48 h in culture. Neurons preferentially adhere to the 1-40 and 
25-35 ~-amyloid peptides over the surrounding laminin alone sub-
strate (n = 18). With the scrambled 1-40 and 25-35 peptides, no cells 
were observed to adhere to the spot when this peptide was used as a 
substrate (n = 15). After conditioning by exposure to cortical glial 
cells for 14 days, the 25-35 peptide spot showed a very much dimin-
ished ability to support neuron attachment (n = 21). 
43 amino acid {3-amyloid molecule and followed their 
responses using a plaque-like "spot" assay. Cortical neu-
rons seeded onto spots of 1-40 or 25-35 {3-amyloid pep-
tides showed a marked preferential adherence to the 
peptide surface over the surrounding laminin substrate 
(Figs. 1 and 3A). By contrast, cortical neurons seeded at 
similar cell densities on the scrambled 1-40 or scram-
bled 25-35 peptides did not adhere at all. This suggested 
that neuronal cells of the cortex have an adhesive affin-
ity for the 1-40 amino acid sequence of the {3-amyloid 
molecule, and that this affinity may be mediated by the 
25-35 sequence of the {3-amyloid molecule. 
Behavior of Cortical Glia on {3-Amyloid Substrates 
When glial cells were seeded onto the 25-35, 1-40, 
scrambled 25-35, or scrambled 1-40 amino acid pep-
tides of the {3-amyloid molecule, they initially attached 
and spread on all of the peptide surfaces showing no 
preference for the peptide spots over the surrounding 
laminin substrate. However, time-lapse videomicro-
scopy of the glial cultures on each of the nonscrambled 
amyloid components showed that glial cells exhibit dif-
ferent behaviors on the peptide substrates compared to 
cells off the peptide spots. Within a matter of hours, 
cells resident on the peptide spots underwent a pro-
found change in morphology by producing many elon-
gated processes. In addition, the motility of cells on the 
peptides dramatically increased relative to those seeded 
away from the spot. During their time on the 25-35 and 
1-40 peptides some cells showed alternating periods of 
motility and quiescence. However, even during the sta-
tionary phase, these cells showed a pronounced ruffling 
of the cell surface not shown by cells off the spots. Glial 
cells traversed the border on and off the peptide sub-
, 
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FIG. 2. Change in relative glial cell density on .a-amyloid peptide spots in vitro. Each bar represents an equivalent number of cells. 
Changes in the ratio of cells on the peptide spot to regions away from the spot per unit area are shown by the intersection with the abscissa. On 
the 1-40 and 25-35 peptide spots, cells remain resident for many days but gradually the density on these peptides declines at comparable rates 
(n = 46). Cells on the scrambled 1-40 and 25-35 peptide spots remain at similar densities as on the surrounding substrate (n = 12) .. 
strate freely, indicating that the border of the peptide 
was not a physical barrier to cell movements and that 
the peptides were not inherently nonadhesive or repul-
sive to glial cells. Glial cells do not exhibit increased 
motility or the same changes in morphology in prepara-
tions of scrambled 25-35 or scrambled 1-40 peptides. 
With time, the density of glial cells on the 1-40 or 25-35 
peptide substrate decreases relative to the cell density 
off the spot (Fig. 2). This appears to occur by cells on the 
peptide spots eventually wandering off the peptides 
without returning. Cells left on these peptides some-
times form aggregates on the peptide surface which is 
not seen by cells off the spots. Thus, time-lapse video-
microscopy revealed glial cells to have altered behavior, 
in terms of cell movements and morphologies, on the 
1-40 and 25-35 peptides. This seemingly "reactive" be-
havior on the 1-40 and 25-35 ,a-amyloid peptide spots 
led us to examine the possibility that glial cells had initi-
ated the deposition of gliotic scar components while in 
contact with the ,a-amyloid peptides. 
Cortical Glia Condition ,a-Amyloid Substrates by ECM 
Deposition 
After 14 days exposure of the 25-35 and 1-40 peptide 
spots, glial cells were replaced with cortical neurons. 
Unlike cortical neurons seeded directly onto uncondi-
tioned 25-35 and 1-40 peptides, cells now failed to show 
an adhesive preference for the preconditioned spot, 
with far fewer cells adhering to the spot than the 
surrounding laminin substrate (Figs. 1 and 3B). Control 
spots left in culture for the same time period but without 
exposure to glial cells still permitted preferential neu-
ron adhesion. This indicated that the surface of the pep-
tide spot exposed to glia had become an unfavorable 
substrate to the attachment and growth of neurons as a 
consequence of glial reactivity. 
We therefore tested glial-conditioned 25-35 and 1-40 
peptide spots for the presence of glycosaminoglycan-
bearing proteoglycans, an indicator of functionally 
reactive gliotic scar formation after trauma (21). After 5 
days in culture, chondroitin sulfate-containing proteo-
glycan deposition could be seen at points of cell contact 
with the peptide (Fig. 4). The deposition of chondroitin 
sulfate proteoglycan on the peptide spots increased with 
longer exposures to glial cells (Fig. 5). Over the surface 
of the peptide spots irregularly shaped, cell~sized 
blotches of chondroitin sulfate-containing proteoglycan 
were found (Fig. 5A) and the complete circumferences 
of the 25-35 and 1-40 peptides were eventually "walled 
off" by high amounts of chondroitin sulfate deposition 
after 14 days in culture (Figs. 5B and 5C). Chondroitin 
sulfate-containing proteoglycan was not deposited on 
scrambled 1-40 and scrambled 25-35 peptides over com' 
parable time periods. Thus, we propose that glial cells 
become reactive when they are in contact with immobi-
lized 1-40 and 25-35 peptides of the ,a-amyloid molecule 
and that this reactivity is manifested by the local deposi-
tion of enhanced amounts of chondroitin sulfate-bear-
ing proteoglycan. Since analysis of time-lapse films re-
vealed no apparent difference in the rates of mitosis 
between cells on the peptide spots and those off tlie 
spots, this form of reactive gliosis is associated with a 
large increase in cell motility but without any discern-
ible increase in cell numbers. 
r 
FIG. 3. Video prints of cortical neurons cultured on immobilized 25-35 ,6-amyloid peptides. (A) Cortical neurons 48 h postseeding on a 25-35 
peptide spot. Relatively more neuronal processes and cell bodies are found on the peptide surface than away from the spot. (B) Cortical neurons 48 h 
postseeding on a 25-35 peptide spot which had been previously exposed to mixed glia for 14 days. Unlike A, cells preferentially adhere to the 
surrounding substrate rather than the conditioned peptide surface. Inset at low power magnification shows conditioned peptide surface to be largely 
devoid of neuronal cells. Scale bars: A, 50 .um; B, 50 .um. 
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FIG. 4. Deposition of chondroitin sulfate-containing proteoglycan by cortical glial cells on {3-amyloid peptide spots in vitro. (A) A 25-35 
~-amyloid peptide, (B) 1-40 {3-amyloid peptide sequence. Chondroitin sulfate positivity is shown in red and GFAP positivity is shown in 
yellow-green. As cells approach the peptide spot from the side, chondroitin sulfate can be seen at the points of contact of the cells with the 
peptide border (A, arrow). This becomes progressively more intense with time, as cells migrate along and over the edge of the peptide (B, 
arrow). The bright green spots in A and B are fluorescent spheres endocytosed by glial cells used for tracking during timelapse videomicro-
SCOpy. Scale bars: A, 5 ~m; B, 10 ~m. 
FIG. 5. Deposition of chondroitin sulfate-containing proteoglycan on immobilized 25-35 {3-amyloid peptide spots in vitro after 14 days 
exposure to cortical glial cells. Chondroitin sulfate positivity is shown in red (A, B, and C) and GFAP positivity is shown in yellow-green (B and 
C). (A) On the surface of the peptide after 14 days, localized areas of chondroitin sulfate deposition are left on the peptide surface showing that 
the surface has been subjected to glial reactivity. The complete circumference of the peptide spot and much of the surface is coated with 
chondroitin sulfate (B and C), areas which time-lapse videomicroscopy has shown to be repeatedly contacted by glial cells. The orange hue of 
the peptide spots is an artifact of long camera exposures during fluorescence photography. Scale bars: A, 20 ~m; B, 100 ~m; C, 10 ~m. 
FIG. 7. Immunolocalization of chondroitin sulfate proteoglycan in sections from cortex and hippocampus of patients diagnosed with 
Alzheimer's disease. (A) Hippocampus: Chondroitin sulfate proteoglycan (brown) is found in intimate association with numerous. senile 
Plaques (arrow). (B) Cortex: GFAP-positive astrocytes and astrocytic processes (purple-mauve stain; arrows) are located near the periphery of 
~enile plaques (brown stain). Scale bars: A, 50 ~m; B, 25 ~m; C, 10 ~m. (C) Hippocampus: Higher magnification of a solitary senile plaque 
Illllllunostained with monoclonal3B3 and Congo red. Birefringence of Congo red identifies the {3-amyloid core as the cross-shaped structure in 
the center of the plaque. Chondroitin sulfate proteoglycan is located primarily around the periphery (brown). 
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FIG. 6. Reactive gliosis to nitrocellulose filters saturated with J3-amyloid peptide implanted into the cortex of neonatal rats. GFAP 
positivity is found at comparable levels in both the J3-amyloid-impregnated filter CA) and control filter CC), showing that glial cells infiltrate 
both experimental and control filters. However, only the J3-amyloid-containing filter elicits a significant deposition of chondroitin sulfate CB), 
which stains more intensely than the control filter without J3-amyloid CD). Scale bars: A, 500 I-'m; B, 800 I-'m; C, 500 I-'m; D, 800 I-'m. 
In Vivo Response to Immobilized fJ-Amyloid 
We then examined whether chondroitin sulfate pro-
teo glycan is also deposited in excess in response to the 
presence of fJ-amyloid in intact tissue. Neonatal rats, 
which do not form chondroitin sulfate-containing scars 
after lesions to the cortex (21), were implanted with ni-
trocellulose filters impregnated with 1-40 fJ-amyloid 
and allowed to survive 30 days (21, 22). Approximately 
the same number of GFAP-positive processes and cells 
were seen infiltrating control and fJ-amyloid implants 
(Figs. 6A and 6C). However, fJ-amyloid filters contained 
significant amounts of chondroitin sulfate-containing 
proteoglycan while comparable control filters revealed 
little or no staining (Figs. 6B and 6D). Thus, glial cells in 
intact living tissue react to the presence of fJ-amyloid by 
producing chondroitin sulfate-bearing proteoglycan in a 
manner similar to glia confronted with fJ-amyloid in 
vitro. 
Chondroitin Sulfate Proteoglycan in Human AD Tissue 
The finding that fJ-amyloid peptides induce enhanced 
deposition of chondroitin sulfate proteoglycan in the 
cortex ofliving rats, even when removed from the direct 
effects of trauma, prompted us to search in human tis-
sue for the association of chondroitin sulfate proteogly-
can with senile plaques in AD patients. Using antibodies 
against various glycosaminoglycan portions of chon-
droitin sulfate proteoglycan, we found greatly enhanced 
amounts of chondroitin sulfate proteoglycan at the pe-
riphery of senile plaque cores (Fig. 7). Bearing some 
similarity to our in vivo filter implants, the proteoglycan 
was found to be associated with GF AP-positive astro-
cytes in the near vicinity of senile plaques (Fig. 7C). 
Importantly, this distribution of chondroitin sulfate pro-
teo glycan corresponds closely to the region around se-
nile plaques which has both a decline in neuritic density 
and an increase ofaxons exhibiting AD-associated cyto-
skeletal damage (2). Therefore, it appears likely that the 
same events of reactive gliosis and deposition of chon-
droitin sulfate proteoglycan are taking place in the AD 
brain as in our in vitro and in vivo models. 
DISCUSSION 
Our study has focused on the possibility that neuritic 
retraction and/or neuronal dystrophy associated with 
Alzheimer-like plaques is not simply a consequence of 
,B-AMYLOID INDUCES GLIOSIS 297 
direct neurotoxicity by ,B-amyloid (as it has been sug-
gested in solution (15, 20, 34-36) or as insoluble peptide 
aggregates (8, 24), but also of secondary glial cell reac-
tions to the insoluble molecule. The ,B-amyloid peptides 
I were bound to a substrate in our experimental model 
systems and, therefore, it may be argued that this pre-
sentation of ,B-amyloid peptides to cortical cells more 
closely mimics the situation of AD plaques in vivo where 
p-amyloid is present in fibrillar form. We have shown j for the first time that ,B-am~loid peptide ~s able to ~nduce 
I glial cells to become functlOnally reactIve both m cul-
~ ture and in the intact animal in that they specifically 
deposit enhanced quantities of chondroitin-6-sulfate 
proteoglycan, a known inhibitor of neuronal regenera-
tion found in glial scars. We propose that the chondroi-
tin sulfate proteoglycan present around senile plaques 
of patients with AD, perhaps along with other proteogly-
cans previously described in association with senile 
plaques (8, 24, 29-31), may be a link in the chain of 
events that ultimately leads to neuronal dystrophy and 
possibly neuronal loss. 
The distinguishing feature by which ,B-amyloid is able 
to act as an inducer of reactive gliosis is an especially 
important but perplexing problem in light of the recent 
observation that the ubiquitiously distributed (33) amy-
loid precursor protein (APP), from which ,B-amyloid is 
abherrantly cleaved, may itself be a chondroitin sulfate-
bearing proteoglycan core protein (27). If this were the 
case, then deposition of APP by a variety of injured cells 
of which there is some evidence (14, 28) could be a global 
initiator of scar formation in the CNS if the molecule 
were fragmented and modified extracellularly (by mi-
croglia or reactive astrocytes (1)), perhaps in response 
to the abnormal presence of a proteoglycan core pro-
tein. In this way, ,B-amyloid could be considered to be a 
molecular trigger of gliosis among other candidate mole-
cules such as cytokines and growth factors (11, 17). It 
remains to be determined whether gliosis triggered by 
~-amyloid results in the deposition of a variety of scar-
associated molecules including different species of pro-
teoglycans along with other extracellular matrix mole-
CUles such as tenascin (21). In the AD brain, such a pro-
cess may explain why plaque-associated axonal damage 
extends out and away from the dense ,B-amyloid core (2) 
into the reactive astroglial areas and why characteristic 
neuritic dystrophy occurs specifically in response to ,B-
amYloid deposition (3). Furthermore, our findings that 
~-amyloid supports neuronal attachment, perhaps via 
Some modification of laminin (16), unless conditioned 
?yglia suggests that the extracellular matrix surround-
lUg plaques could curtail neurite regeneration in the AD 
.brain. Given the potent inhibitory nature of certain pro-
teoglycans to neuronal cells, especially the inhibition by 
tyPes of chondroitin-6-sulfate proteoglycan (32), this 
Would suggest that glia can play important roles not 
Only in the creation of axonal boundaries during normal 
development, but also in the pathology of CNS lesions 
and neurodegenerative disorders such as Alzheimer's 
disease. 
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